Biotechnology
CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market
CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash., Oct. 11, 2022 /PRNewswire/ -- CSafe, one of the largest active and passive temperature-controlled shipping solutions providers for pharmace...
Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days to 150 days LEIDEN...
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Oct. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina has approved ...
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60 subjects in 6 dose escalation cohorts and 12 subjects in food effect trial. The enrollment is expected to be completed in the fourth quarter of 2022 --ASC10 is an oral double prodrug. After oral ...
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes
HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical trial ev...
Raffles Medical Group and NalaGenetics Provide Pre-emptive Genetic Testing for Adverse Drug Reactions
* Raffles is the first hospital in Singapore to provide pre-emptive pharmacogenomics testing protocol * Aims to reduce side effects due to inappropriate medications SINGAPORE, Oct. 7, 2022 /PRNewswire/ -- Raffles Medical Group (RMG) is collaborating with biotech start-up NalaGenetics to offer...
Servier unveils its 2030 ambition and reveals a new visual identity
* A new ambition by 2030 to accelerate its transformation dynamic * A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal PARIS, Oct. 6, 2022 /PRNewswire/ -- Servier today unveils its 2030 ambition as well as a new visual identity that reflec...
Winners of F3 Challenge, Global Seafood Industry's Contest, Announced
Carnivores, the largest consumers of fishmeal, fish oil were focus of industry contest SEATTLE, Oct. 6, 2022 /PRNewswire/ -- The F3 — Future of Fish Feed announced today that three animal feed manufacturers—Star Milling Co, Empagran and Jiangsu Fuhai Biotech Co, Ltd.—each won aUS$100,000 grand p...
Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH
-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroid hormone receptor β (THRβ) agonist drug candidate for non-alcoholic steatohepatitis (NASH). ASC41 Phase II clinical trial is currently the most advanced 52-week Phase II clinical trial which is in...
Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA)
Phase 1 supporting data indicated an encouraging profile and confirmed the dual mechanism of action achieved through targeting both the alternative and terminal complement pathways CAMBRIDGE, Mass., Oct. 3, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering tran...
DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Debiopharm awards the winning scientists for the JCA (Japanese Cancer
Association) Award for innovative, disruptive, and translational oncology
research
LAUSANNE, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.
* Transaction values YS Biopharma at pre-money equity value of $834 million * Certain investors ("Forward Purchase Investors") are expected to invest $30 million in a private placement concurrently with the closing of the business combination transaction pursuant to certain forward purchase ag...
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts
WORCESTER, Mass., Sept. 29, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), held a topping-off ceremony, in partnership with the Worcester Business Development Corporation (WBDC), to mark the completion of...
Green Mountain Biotech and Kamedis Announce First Patent in China for Unique Herb-Based Acne and Skin Relief Solution
Clinically-tested solution, based on a proprietary blend of six herbs used in
Traditional Chinese Medicine, helps relieve symptoms of acne and other skin
inflammation conditions.
TEL AVIV, Israel, Sept. 29, 2022 /PRNewswire/ -- Green Mountain Biotech
ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world
* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve survival for patients with ES-SCLC. * In ASTRUM-005, serplulimab combined with chemotherapy achieved by far the longest OS in first-line immunotherapy for ES-SCLC. Compared with chemotherapy, the...
ICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY FOR ISB 1442
First patient dosed with novel biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, today anno...
Advanced Instruments Introduces Solentim VIPS™ PRO, A High Efficiency Single Cell Seeder to Optimize Cell Line Development Workflows
VIPS PRO delivers powerful and efficient seeding technology and definitive proof of monoclonality for workflow productivity and confidence. NORWOOD, Mass., Sept. 28, 2022 /PRNewswire/ -- Advanced Instruments today announced the launch ofSolentim VIPS PRO, a high efficiency single cell seeder, at...
Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost
SINGAPORE, Sept. 28, 2022 /PRNewswire/ -- On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a base to develop the company's immunotherapy assets to address unmet needs in cancer treatment. Located in Solaris @ Tai Seng, this 1,300 square metres faci...
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
CAMBRIDGE, England and COPENHAGEN, Denmark, Sept. 28, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S ("Contera") are pleased to announce a strategic drug discovery collaboration on an undisclosed target. Under the terms of the...
Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib
The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharmi...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Multiple achievements made in China-Hungary BRI conference
[Picked up by 309 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 280 media titles]
2024-05-03 06:25Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39